EX-10.2 3 dex102.htm THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT Third Amended and Restated Employment Agreement by and between Immunomedics, Inc. and Dr. David M. Goldenberg Dated as of July 1, 2011 Page THIRD AMENDED AND RESTATED EMPLOYMENT...

EX-10.2 3 dex102.htm THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT

Exhibit 10.2

Third Amended and Restated Employment Agreement

by and between Immunomedics, Inc. and

▇▇. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇

Dated as of July 1, 2011

TABLE OF CONTENTS


		Page

1.	Employment		4

2.	Term		4

3.	Duties		4

4.1.	Compensation		5

4.2.	Additional Incentive Compensation		6

5.	Vacation and Fringe Benefits		9

6.	Research Contracts or Grants		9

7.	Prior Inventions and Discoveries		9

8.	Arbitration		10

9.	Restrictive Covenants		10

10.	Termination		13

11.	Decisions and Determinations of the Board		14

12.	Cooperation with Immunomedics After Expiration or Termination		14

13.	Payment and Benefits on Termination or Expiration		15

14.	[INTENTIONALLY OMITTED]		17

15.	Parties in Interest		17

16.	Notices		18

17.	Governing Law		19

18.	Captions; Word Meanings		19

19.	Miscellaneous		19



20.	Binding Effect	19

21.	Entire Agreement	20

22.	Severability	20

23.	Survival of Provisions	20

24.	Counterparts	20

THIRD AMENDED AND RESTATED

EMPLOYMENT AGREEMENT

This THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“this Agreement”) is made and entered into as of July 1, 2011 (the “Effective Date”), by and between IMMUNOMEDICS, INC., a Delaware corporation with its principal office and place of business in ▇▇▇▇▇▇ Plains, New Jersey (“Immunomedics” or the “Company”) and ▇▇. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇, an individual presently residing in Mendham, New Jersey (“▇▇. ▇▇▇▇▇▇▇▇▇▇”).

PREMISES

WHEREAS, ▇▇. ▇▇▇▇▇▇▇▇▇▇ founded Immunomedics in 1982 and continuously since that time, has served as the Chair of its Board of Directors, as an executive of the Company, and as a significant shareholder of the Company; and

WHEREAS, ▇▇. ▇▇▇▇▇▇▇▇▇▇ invented and developed substantially all of the technology, and obtained the patents, on which Immunomedics’ business is based; and

WHEREAS, the parties entered into the Second Amended and Restated Employment Agreement, dated December 17, 2008 (the “Second Amended and Restated Agreement”), as amended by that certain amendment dated December 22, 2010; and

WHEREAS, the parties desire to amend and restate the terms and conditions of the Second Amended and Restated Agreement in its entirety in order to reflect certain desired changes and clarifications in the terms and continue ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment with the Company upon the amended and restated terms and conditions of this Agreement; and

WHEREAS, ▇▇. ▇▇▇▇▇▇▇▇▇▇ acknowledges that he has had an opportunity to consider this Agreement and consult with an independent advisor(s) of his choosing with regard to the terms of this Agreement, and enters into this Agreement voluntarily and with a full understanding of its terms; and

WHEREAS, the Company and ▇▇. ▇▇▇▇▇▇▇▇▇▇ have agreed that this Agreement will supersede and replace the Second Amended and Restated Agreement as of the Effective Date.

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Employment. Immunomedics agrees to continue the employment of ▇▇. ▇▇▇▇▇▇▇▇▇▇, and ▇▇. ▇▇▇▇▇▇▇▇▇▇ accepts such continued employment, upon the terms and conditions set forth in this Agreement.

2. Term. Unless earlier terminated by either party pursuant to Section 10, this Agreement will continue for a five (5) year period (through July 1, 2016) (the “Term”). For purposes of this Agreement, “Contract Year” is defined as a period of twelve (12) consecutive calendar months beginning on July 1, 2011, or any anniversary thereof, and ending on the last day of the twelfth month thereafter. For purposes of this Agreement, “Term of Employment” shall mean the length of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ total employment from original hire through the end of the Term or through the date of termination if this Agreement is terminated during the Term pursuant to Section 10.

3. Duties.

(a) Description. Throughout the Term of this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall serve as Chief Scientific Officer and Chief Medical Officer of Immunomedics and shall perform such duties in these roles, which are commensurate with ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ expertise, experience, roles fulfilled within the Company, and professional standing and the needs of the Company from time to time, as the Board of Directors of Immunomedics (the “Board”), in consultation with ▇▇. ▇▇▇▇▇▇▇▇▇▇, may determine from time to time. The Board may assign specific duties to ▇▇. ▇▇▇▇▇▇▇▇▇▇ after a review of Immunomedics’ needs. ▇▇. ▇▇▇▇▇▇▇▇▇▇ will report directly to the Board throughout the Term of this Agreement. Immunomedics reserves the right, subject to Section 10(f) below, to modify, but not diminish, the nature and scope of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ duties to meet the Company’s changing needs, provided that such duties and level of authority shall remain commensurate with ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ expertise, experience and professional standing. If elected to such positions, ▇▇. ▇▇▇▇▇▇▇▇▇▇ may serve as a member of the Board, and as an executive officer and director of any subsidiary or affiliate of or successor to Immunomedics and, in the Board’s discretion, may be paid additional, reasonable compensation for such services.

(b) Best Efforts. Throughout the Term of this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall faithfully, industriously and to the best of his ability, experience and talents, perform all of the duties contemplated by this Agreement and in accordance with his fiduciary duties as an officer and director of the Company. In the course of performing such duties, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall cooperate fully, to the best of his ability, with the Board and all officers, agents and employees of Immunomedics in all matters connected with the business of Immunomedics.

(c) Extent of Duties. ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall devote such time to Immunomedics as is reasonably necessary to fulfill the duties contemplated by this Agreement. Notwithstanding any language to the contrary, Immunomedics acknowledges and authorizes ▇▇. ▇▇▇▇▇▇▇▇▇▇ to perform the following roles and to dedicate the time necessary to perform such roles, the scope of which Immunomedics acknowledges and agrees does not materially interfere with his performance of duties directly for Immunomedics:

(i) To serve as a member of the Board of Trustees of and to be employed (including without limitation as the President and/or Chief Executive Officer) by the Center for Molecular Medicine and Immunology (a/k/a Garden State Cancer Center) or any of its subsidiaries, affiliates, successors or any non-profit substitute entity (collectively the “Center”), provided, that any such subsidiary, affiliate, successor or non-profit substitute entity agrees to undertake all of the obligations of the Center pursuant to any existing or future license, proprietary rights or other equivalent agreement between Immunomedics and the Center.

(ii) To serve as a member of the Board of Directors of and to be employed (including without limitation as an executive officer) by the Company’s majority-owned subsidiary, IBC Pharmaceuticals, Inc. (“IBC”).

Immunomedics acknowledges that ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall be entitled to spend such time as is necessary to fulfill his duties for the Center and IBC, provided that such duties do not materially interfere with his ability to perform any of his obligations under this Agreement. Such activity on behalf of the Center, and his activity on behalf of IBC to the extent consistent with the provisions hereof, shall not be deemed a breach of this Agreement. Any salary, fees or other income paid by the Center and IBC to ▇▇. ▇▇▇▇▇▇▇▇▇▇ in his respective capacity in each such entity shall be the property of ▇▇. ▇▇▇▇▇▇▇▇▇▇ and shall not diminish the compensation due him hereunder.

4.1. Compensation.

(a) Base Salary. In consideration for services rendered by ▇▇. ▇▇▇▇▇▇▇▇▇▇ pursuant to this Agreement, Immunomedics will pay ▇▇. ▇▇▇▇▇▇▇▇▇▇ a base salary at the rate of Five Hundred Twenty Five Thousand Dollars ($525,000.00) per Contract Year, payable in accordance with the Company’s regular payroll procedures (the “Base Salary”). The Board or the Compensation Committee of the Board (the “Compensation Committee”) will review ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ Base Salary annually for appropriate increases, pursuant to the Company’s standard performance review policies for senior level executives.

(b) Annual Bonus. Throughout the Term of this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will be eligible to participate in the Company’s incentive compensation plan for senior level executives (the “Incentive Plan”) in accordance with the terms of the Incentive Plan. The Company reserves the right to amend or rescind its Incentive Plan at any time in its discretion, but will provide ▇▇. ▇▇▇▇▇▇▇▇▇▇ written notice of any changes at the same time and in the same manner as other Incentive Plan participants as may be required by law or regulation. In connection with his participation in the Incentive Plan, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will be eligible to receive an annual discretionary bonus, as determined by the Compensation Committee, based on its assessment of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ individual performance and the Company’s overall performance. ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ Annual Bonus Target is 50% of Base Salary, with a potential Bonus ranging from 0 to 150% of the Annual Bonus Target, conditional upon his achievement of performance goals as the Compensation Committee may establish and determine. The Compensation Committee will determine the amount of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ discretionary annual bonus, if any, as of the end of each fiscal year during the Term of this Agreement, and shall pay such Bonus as soon as practicable after such determination, but in no event later than 2.5 months after the end of each fiscal year, subject to the termination provisions contained in Section 10 of this Agreement.

(c) Equity Compensation. Throughout the Term of this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ is eligible to receive awards pursuant to the Company’s 2006 Stock Incentive Plan or any successor equity compensation plan of the Company, in amounts as determined by the Compensation Committee. Awards granted to ▇▇. ▇▇▇▇▇▇▇▇▇▇, if any, will be subject to the provisions of the Company’s 2006 Stock Incentive Plan (including any amendments and/or successor equity plan(s) of the Company), as well as any separate option agreement, restricted stock purchase agreement or stock award agreement between ▇▇. ▇▇▇▇▇▇▇▇▇▇ and the Company, which states the terms and conditions of each such award (e.g., exercise price, expiration date, vesting schedule or stock options, and any restricted period and\or other restrictions such as performance objectives relating to stock awards). Nothing in this section shall impact or affect any equity compensation awards ▇▇. ▇▇▇▇▇▇▇▇▇▇ may have received at any earlier time during his Term of Employment.

4.2. Additional Incentive Compensation. In recognition of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ past and future integral involvement in and contribution to all aspects of Immunomedics’ scientific and creative activities, the Company shall make the following payments to ▇▇. ▇▇▇▇▇▇▇▇▇▇ as additional incentive compensation (“Additional Incentive Compensation”).

(a) The Additional Incentive Compensation payments to which ▇▇. ▇▇▇▇▇▇▇▇▇▇ is entitled include:

(i) Transactional Payments; Net Revenue Payments. With respect to any fiscal year during the Term of the Agreement in which Immunomedics records an annual net loss (determined by Immunomedics in a manner consistent with generally accepted accounting principles (“GAAP”) for the entire fiscal year as audited by Immunomedics’ independent registered public accounting firm), Immunomedics will pay to ▇▇. ▇▇▇▇▇▇▇▇▇▇ a sum equal to three quarters of one percent (.75%) of the total Consideration the Company receives from any third party transaction, excluding third party financing transactions and any Disposition of Undeveloped Assets. With respect to any fiscal year during the Term of the Agreement in which Immunomedics records positive net income (determined by Immunomedics in a manner consistent with GAAP) for the entire fiscal year as audited by Immunomedics’ independent registered public accounting firm, Immunomedics will pay to ▇▇. ▇▇▇▇▇▇▇▇▇▇ a sum equal to one and one-half percent (1.5%) of Immunomedics’ Annual Net Revenue (as defined in Section 4.2(d)) for each such fiscal year (unless ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment terminates pursuant to Sections 10(a) or 10(e)), and thereafter throughout the non-competition period (as defined in Section 9(b)); and

(ii) Patent Lifetime Royalty Payments. Immunomedics will pay to ▇▇. ▇▇▇▇▇▇▇▇▇▇ for each full fiscal year of the Company, a sum equal to a percentage of the annual Product Royalties the Company receives each such fiscal year on each of the products for which ▇▇. ▇▇▇▇▇▇▇▇▇▇ is an Inventor, and all products using, related to or derived from products for which ▇▇. ▇▇▇▇▇▇▇▇▇▇ is an Inventor (“Patented Products”), which payments shall continue for each Patented Product for the remaining Life of the Patent covering each Patented Product (collectively “Patent Lifetime Royalty Payments”). The percentage of Product Royalties that Immunomedics will pay to ▇▇. ▇▇▇▇▇▇▇▇▇▇ on each Patented Product will be determined based on the percentage of Product Royalties that Immunomedics must pay to external third parties (any party other than a wholly owned subsidiary of Immunomedics) on each Patented Product, as follows:

(A) One percent (1%) of annual Product Royalties on Patented Products for which the Company pays a Royalty of more than 9.0 % to external third parties;

(B) One and one-half percent (1.5%) of annual Product Royalties on Patented Products for which the Company pays a Royalty of more than 6.0 % through 9.0 % to external third parties;

(C) Two percent (2%) of annual Product Royalties on Patented Products for which the Company pays a Royalty of more than 3.0% through 6.0 % to external third parties; or

(D) Three percent (3%) of annual Product Royalties on Patented Products for which the Company pays a Royalty of 3.0% or less to external third parties.

Patent Lifetime Royalty Payments under Section 4.2(a)(ii) shall be due and owing from Immunomedics to ▇▇. ▇▇▇▇▇▇▇▇▇▇ (or his estate or designated beneficiaries) throughout the Life of each Patent both during his employment with the Company and after his employment terminates, except that Lifetime Royalty Payments shall not be payable in the event an arbitrator or court finds that ▇▇. ▇▇▇▇▇▇▇▇▇▇ committed a material breach of his covenants contained in Section 9. During the Term of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment with Immunomedics only, any

quarterly payment of Patent Lifetime Royalty Payments calculated under this Section 4.2(a)(ii) will be paid to ▇▇. ▇▇▇▇▇▇▇▇▇▇ (or his estate or designated beneficiaries) only to the extent that such Patent Lifetime Royalty Payments exceed the quarterly Minimum Payment paid to him pursuant to Section 4.2(c).

(b) Payments Upon Disposition of Undeveloped Assets. In the event the Company, with its Board’s approval, completes a Disposition during the Term of Employment, or within three (3) years thereafter, of any one or more of Immunomedics’ Undeveloped Assets for which ▇▇. ▇▇▇▇▇▇▇▇▇▇ was an Inventor, Immunomedics will pay ▇▇. ▇▇▇▇▇▇▇▇▇▇ (or his estate or designated beneficiaries) a sum equal to at least twenty percent (20%), or more (as determined by the Board), of the Consideration Immunomedics receives from each Disposition, upon receipt; provided, however that no such payment shall be due in the event an arbitrator or court finds that ▇▇. ▇▇▇▇▇▇▇▇▇▇ committed a material breach of his covenants contained in Section 9. Subject to the preceding conditions, the Company’s obligation to compensate ▇▇. ▇▇▇▇▇▇▇▇▇▇ (or his estate or designated beneficiaries) under this provision, if any, applies to all Dispositions completed within the Term of Employment or within three (3) years thereafter, even if the Company actually receives the Consideration at some time after the three (3) year period elapses.

(c) Minimum Payment. Immunomedics agrees to make a minimum payment of One Hundred Fifty Thousand Dollars ($150,000) to ▇▇. ▇▇▇▇▇▇▇▇▇▇ during each of Immunomedics’ fiscal years during the Term of this Agreement, payable in equal quarterly payments, as an advance against the amounts due to ▇▇. ▇▇▇▇▇▇▇▇▇▇ pursuant to Section 4.2(a) and (b) above. This minimum payment shall be prorated for any partial fiscal year of Immunomedics or partial year of service of ▇▇. ▇▇▇▇▇▇▇▇▇▇ covered by this Section 4.2.

(d) Definitions. As used in this Agreement, the following terms shall have the following meanings:

(i) “Annual Net Revenue” means Immunomedics’ total revenue determined for the fiscal year as determined by GAAP less (i) Consideration received upon Disposition of Undeveloped Assets, (ii) Product Royalties on Patented Products (as defined in Section 4.2(a)(ii)) and (iii) amounts recorded as revenue by Immunomedics during such fiscal year that are related to payments previously paid to ▇▇. ▇▇▇▇▇▇▇▇▇▇ under Section 4.2(a)(i) in any prior period. Further, Annual Net Revenue shall not include (A) net sales of any Acquired Asset, (B) any amounts received as cost reimbursement payments, and (C) any revenue generated from interest or investment income of the Company.

(ii) “Acquired Asset” means any product, technology or business to which Immunomedics acquired the rights from any third party (other than a wholly-owned subsidiary of Immunomedics), or affiliated group of such third parties, for an aggregate consideration in excess of Five Million Dollars ($5,000,000), provided that Immunomedics did not materially contribute to the invention or development of such asset prior to such acquisition. For purposes of this definition, Immunomedics will be deemed to have materially contributed to any product, technology or business which is covered by any Immunomedics’ patent.

(iii) “Consideration” means cash, asset(s) or property, tangible or intangible, which Immunomedics receives directly or indirectly, for a Disposition (the transfer of relevant assets), including but not limited to sales proceeds, license fees and licensing milestones, other milestone payments, up-front fees and sales bonuses. Consideration shall not include: (A) any consideration for or with respect to any Acquired Asset, (B) amounts paid to Immunomedics which clearly are intended to constitute reimbursement of direct out-of-pocket costs incurred by Immunomedics for research, development or preclinical or clinical trials of the product or products which are the subject of the Disposition, regardless of whether paid directly or indirectly, and however labeled, provided such amounts are paid pursuant to an agreement in effect at the time of such payment(s) and (C) any Patent Lifetime Royalty Payments (as defined in Section 4.2(a)(ii)). In calculating the value of Consideration received in a Disposition, Immunomedics will offset the value of any thing of value that it had to grant or provide to the other party in exchange for the Disposition as an express element of the transaction. The parties agree that any dispute with respect to the value of Consideration received in connection with any Disposition or any other dispute arising under this definition shall be submitted to arbitration pursuant to Section 8.

(iv) “Disposition” means any transfer, by way of sale, license or otherwise, to an unaffiliated third party, of any of Immunomedics’ right, title or interest in or to any one or more of its products, technologies, intellectual property, businesses or other assets. Disposition includes any arrangements,

whereby, Immunomedics combines with another entity and forms a new entity in which Immunomedics holds any ownership interest and to which Immunomedics transfers, by way of sale, license or otherwise, any of Immunomedics’ right, title or interest in or to any one or more of its products, technologies, intellectual property, or businesses. “Disposition” shall not include a transfer of all or substantially all of the assets or stock of Immunomedics pursuant to a Change in Control (as defined in Section 10(f)) or similar corporate transaction of Immunomedics or to which it is a party.

(v) “Inventor” means a person(s) identified as an inventor of a patented product, formula or idea on the disclosures initially filed in the relevant patent office(s) for such patent.

(vi) “Life of a Patent” means the period beginning the first date on which a patent application is filed in any patent office covering any territory in the world and continuing as long as at least one (1) valid claim of the patent exists in any territory in the world. It is understood that for purposes of this definition, the patent office in which the patent initially is filed is not likely to be located in or covering the same territory in which the last valid patent claim remains, and that the Life of the Patent will cover all time periods between these two events.

(vii) “Product Royalties” means all Consideration designated as a royalty, which Immunomedics receives for the license or use of its technology(ies), products, inventions, patents, or other intellectual property. For purposes of this Agreement, a patent or copyright will be deemed valid in any territory in the world if at least one (1) valid claim of the patent or copyright exists in any territory in the world.

(viii) “Immunomedics” means Immunomedics and all of its direct and indirect subsidiaries or affiliates, including but not limited to IBC.

(ix) “Undeveloped Assets” means any technology, product, agent, intellectual property, business or other asset(s) or product(s) for which, at the time of Disposition, the Board of Directors of Immunomedics and ▇▇. ▇▇▇▇▇▇▇▇▇▇ have mutually determined that Immunomedics (A) is not currently budgeting for development, (B) has not set a time table for development, at a level consistent with the financial support or timetable given to any other major project or technology for which the Company currently is budgeting for either preclinical or clinical development, (C) has not funded with substantial research and development resources, or (D) has not entered Immunomedics’ sponsored Phase I or Phase II clinical trials.

(x) “Code” means the Internal Revenue Code of 1986, as amended.

(e) In Lieu of Other Payments. The Additional Incentive Compensation discussed in Sections 4.2(a)(i) and 4.2(a)(ii) of this Agreement shall be in lieu of all other royalties and percentage payments to which ▇▇. ▇▇▇▇▇▇▇▇▇▇ otherwise previously might have been entitled relative to Undeveloped Assets under prior agreements or otherwise, including but not limited to payments pursuant to the License Agreement or on any other prior agreement between the parties.

(f) Reports and Payments. Within forty-five (45) days after the last day of each of its fiscal quarters (other than the final quarter of each fiscal year), Immunomedics will provide ▇▇. ▇▇▇▇▇▇▇▇▇▇ with a written report that includes a preliminary computation (based upon unaudited financials) of Net Revenue, of Product Royalties, and of royalties on Patented Products (computed for such quarter in the same manner as Annual Net Revenue or annual Product Royalties is to be computed for a fiscal year) and Disposition Payments (if any), and all amounts due to ▇▇. ▇▇▇▇▇▇▇▇▇▇ pursuant to Sections 4.2(a)(i), 4.2(a)(ii), and 4.2(b) with respect to such fiscal quarter. Within two and one half (2 1/2) months after the last day of each of its fiscal years, Immunomedics will provide ▇▇. ▇▇▇▇▇▇▇▇▇▇ with a report that includes computation of Annual Net Revenue, of annual Product Royalties, of annual royalties on Patented Products, and Disposition Payments (if any) for the entire year and all amounts due with respect to that year (based on audited financials), as adjusted for the minimum payment provided to ▇▇. ▇▇▇▇▇▇▇▇▇▇ pursuant to Section 4.2(b) above. Immunomedics will pay or transfer to ▇▇. ▇▇▇▇▇▇▇▇▇▇, within two and one half (2 1/2) months after the last day of each of its fiscal years, all amounts due pursuant to Sections 4.2(a)(i) and 4.2 (a)(ii) with respect to that year. Immunomedics will pay or transfer to ▇▇. ▇▇▇▇▇▇▇▇▇▇ any participation in Consideration to which he is entitled pursuant to Section 4.2(b) above within fifteen (15) calendar days following receipt of such Consideration by Immunomedics, regardless of how the Company may record the receipt of such Consideration for other accounting purposes. Immunomedics will provide such documentation as ▇▇. ▇▇▇▇▇▇▇▇▇▇ deems reasonably necessary to verify the Company’s calculations of the payments due to ▇▇. ▇▇▇▇▇▇▇▇▇▇ pursuant to Sections 4.2(a)(i), 4.2(a)(ii), and 4.2(b). At least once during each fiscal year, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall have the right to obtain access to Immunomedics sales and accounting books and records, and other documents ▇▇. ▇▇▇▇▇▇▇▇▇▇ deems reasonably necessary to confirm Immunomedics’ compliance with its obligations under this Agreement.

5. Vacation and Fringe Benefits.

(a) Vacation. ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall be entitled to a total of six (6) weeks paid vacation during each Contract Year throughout the Term of this Agreement. Vacation benefits are subject to all other terms and conditions of Immunomedics’ standard vacation policies including but not limited to those relating to accrual of vacation time.

(b) Expenses. It is understood that ▇▇. ▇▇▇▇▇▇▇▇▇▇ will incur reasonable and necessary expenses in connection with his employment and Immunomedics will reimburse ▇▇. ▇▇▇▇▇▇▇▇▇▇ for any such expenses in accordance with policies and limits as adopted by the Board.

(c) Employee Benefit Plans. In addition to the benefits expressly mentioned in this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall receive all of the employment-related benefits established by the Board for executive officers and such additional benefits as the Board may award to him from time to time. For purposes of this Agreement, employment-related benefits shall include, without limitation, participation in all employee welfare benefit plans and employee pension benefit plans (as those terms are defined in the Employee Retirement Income Security Act of 1974, as amended), which Immunomedics may maintain from time to time during the Term of Employment.

6. Research Contracts or Grants. During the Term of this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ occasionally may apply for research contracts for which he would be named as principal research scientist or investigator. In such event, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall:

(a) Deliver copies of such applications to Immunomedics prior to submission to the grantor or other contract entity.

(b) Make such changes to application as Immunomedics may reasonably request.

(d) Allow a mutually acceptable representative of Immunomedics to be present and participate in all negotiations related to the proposed contract. All such contracts shall be subject to any internal approval process the Board may establish.

The provisions of this Section 6 shall not be applicable with respect to any research contracts for which ▇▇. ▇▇▇▇▇▇▇▇▇▇ may apply on behalf of the Center.

7. Prior Inventions and Discoveries.

(a) Discoveries. In exchange for Immunomedics’ agreement to provide the Additional Incentive Compensation detailed in Sections 4.2(a)(i), 4.2(a)(ii) and 4.2(b) of this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees to forego any right to any additional compensation or consideration he otherwise would have the right to receive based on any ownership or interest he has in any and all ideas, inventions, improvements, discoveries, developments, products, compounds, compositions, apparatus, methods, formulae, processes, applications or uses that he made or conceived (solely or jointly with another or others or by material contribution thereto in the course of his significant involvement in the direction of Immunomedics’ research and technology programs) during the Term of Employment (collectively “Discoveries”). ▇▇. ▇▇▇▇▇▇▇▇▇▇ acknowledges that any interest he has or had in such Discoveries shall be the sole and exclusive property of Immunomedics, subject to any other applicable provisions of this Agreement or any other agreements between the parties.

(i) Notwithstanding this provision, Immunomedics acknowledges that it does not have any interest in any Discoveries that ▇▇. ▇▇▇▇▇▇▇▇▇▇ made/makes or conceived/conceives (solely or jointly with another or others or by material contribution thereto in the course of any significant involvement in the direction of the Center’s research and technology programs) related to research performed by or for the Center in the course of his duties for the Center (“Center Discoveries”), and with respect to which ▇▇. ▇▇▇▇▇▇▇▇▇▇ has no individual retained interest other than a royalty interest, and regardless of whether Immunomedics also may have an interest in the subject of such research. ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall retain any royalty interest he may have in any Center Discoveries. Immunomedics’ ownership rights in and to any Discovery made or conceived by ▇▇. ▇▇▇▇▇▇▇▇▇▇ (solely or jointly with another or others or by material contribution thereto) in the course of any significant involvement by ▇▇. ▇▇▇▇▇▇▇▇▇▇ in the research or other activities of IBC, shall be only as may be expressly provided in any license, proprietary rights or other equivalent existing or future agreement that may exist between Immunomedics and IBC.

(ii) Notwithstanding this provision (Section 7(a)), Immunomedics further acknowledges that it does not have any interest in any Discoveries (patented or unpatented) that ▇▇. ▇▇▇▇▇▇▇▇▇▇ made/makes or conceived/conceives (solely or jointly with another or others or by material contribution thereto), which are related to research performed by ▇▇. ▇▇▇▇▇▇▇▇▇▇ independent of his duties and responsibilities for Immunomedics or the Center, provided that such Discoveries do not involve or relate to any technologies, research, or products being produced or developed by Immunomedics or by the Center, and provided that neither Immunomedics nor the Center made any material contribution to such Discoveries.

(b) Disclosures. ▇▇. ▇▇▇▇▇▇▇▇▇▇ acknowledges and agrees that he has provided Immunomedics with relevant information regarding all Discoveries covered under this Agreement. ▇▇. ▇▇▇▇▇▇▇▇▇▇ further agrees to provide Immunomedics with relevant information regarding any new Discoveries he might make at any time during the Term of this Agreement and to comply with his fiduciary duties to Immunomedics.

(c) Cooperation of ▇▇. ▇▇▇▇▇▇▇▇▇▇. Both during and following the Term of Employment, upon the request of Immunomedics, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall execute and deliver any documents and give all reasonable assistance which may be essential or desirable to secure to, assign and vest in Immunomedics the sole and exclusive right, title and interest in and to all Discoveries and other intellectual property. Such reasonable assistance may include but not be limited to the execution and delivery of patent applications, assignments, affidavits, priority claims and other documents that Immunomedics, in its sole discretion, may determine are essential or desirable to obtain, maintain and/or defend such patents and to secure to and vest all appropriate rights in Immunomedics. In addition, ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees that during and following the Term of Employment, at the request of Immunomedics, he generally will cooperate, appear and give evidence in any meetings or proceedings which may arise in connection with Immunomedics’ efforts to secure, assign and vest for the Company the sole and exclusive right, title and interest in and to all Discoveries and other intellectual property. Immunomedics agrees to reimburse ▇▇. ▇▇▇▇▇▇▇▇▇▇ for all reasonable expenses he incurs in providing such cooperation to Immunomedics. For purposes of this section, reasonable expenses may include but not be limited to travel costs, out of pocket expenses, and any loss of salary or wages from another employer (if ▇▇. ▇▇▇▇▇▇▇▇▇▇ no longer is employed by Immunomedics). Any legal proceedings in connection with such matter shall be conducted by attorneys chosen and paid by Immunomedics. Correspondingly, Immunomedics will provide all reciprocal support and reasonable assistance to ▇▇. ▇▇▇▇▇▇▇▇▇▇ that he may require to perfect his interest in any patent or Discovery, consistent with the terms of this Agreement.

(d) Dispute Resolution. In the event that a dispute should arise regarding whether any Discoveries are the property of Immunomedics, or belong to the Center, if the relevant parties are not able to reach agreement, they shall submit the dispute to final and binding arbitration pursuant to Section 8 of this Agreement.

8. Arbitration. All disputes arising under this Agreement, other than actions to enforce the restrictions detailed in Section 9, or as otherwise expressly stated in this Agreement, shall be subject to final and binding arbitration between the parties. Such arbitration shall be submitted to a single arbitrator selected by mutual agreement of the parties, and shall be conducted at a mutually agreeable site located within a ten (10) mile radius of Immunomedics’ principal office in ▇▇▇▇▇▇ Plains, New Jersey. All arbitration proceedings shall be conducted pursuant to the American Arbitration Association Rules for Employment Disputes.

9. Restrictive Covenants.

(a) Confidentiality. ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees that his services to Immunomedics were and are of a special, unique and extraordinary character, and that his position places him in a position of confidence and trust with Immunomedics’ customers and employees. ▇▇. ▇▇▇▇▇▇▇▇▇▇ also recognizes that his position with Immunomedics gives him substantial access to Confidential Information (as defined below), the disclosure of which to competitors of Immunomedics would cause Immunomedics to suffer substantial and irreparable damage. Therefore, ▇▇. ▇▇▇▇▇▇▇▇▇▇ recognizes that it is in Immunomedics’ legitimate business interest to restrict ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ use of Confidential Information for any purposes other than the discharge of his employment duties at Immunomedics, and to limit any potential appropriation of Confidential Information by ▇▇. ▇▇▇▇▇▇▇▇▇▇ for the benefit of Immunomedics’ competitors and to the detriment of Immunomedics. Accordingly, ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees as follows:

(i) Throughout the Term of this Agreement and at all times thereafter, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will not at any time reveal to any person or entity any of the trade secrets or confidential information of Immunomedics, or of any third party, which Immunomedics is under an obligation to keep confidential (including but not limited to trade secrets and non-public information regarding inventions, products, designs, methods, know-how, techniques, systems, processes, software programs, works of authorship, customer lists, projects, intellectual property, plans and proposals) (“Confidential Information”), except as may be required in the ordinary course of performing ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ duties as an employee of Immunomedics or for the benefit of Immunomedics, with the Company’s knowledge and consent. ▇▇. ▇▇▇▇▇▇▇▇▇▇ will keep secret all matters entrusted to him and not use or attempt to use any Confidential Information in any manner which may injure or cause direct or indirect loss to Immunomedics.

(ii) Confidential Information shall not include (and the above restrictions shall not apply to): (A) information that at the time of disclosure is in the public domain through no fault of ▇▇. ▇▇▇▇▇▇▇▇▇▇; (B) information ▇▇. ▇▇▇▇▇▇▇▇▇▇ receives from a third party outside of Immunomedics that was disclosed without a breach of any confidentiality obligation; (C) information approved for release by written authorization of Immunomedics; or (D) information that may be required by law or an order of any court, agency or proceeding to be disclosed. In the event that ▇▇. ▇▇▇▇▇▇▇▇▇▇ is requested or required by law or an order of any court, agency or proceeding to disclose Confidential Information, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will provide Immunomedics with prompt notice of such request so that Immunomedics may timely seek an appropriate protective order or waive ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ confidentiality obligations under this Agreement. ▇▇. ▇▇▇▇▇▇▇▇▇▇ will provide reasonable assistance to Immunomedics in the event the Company notifies him that it intends to seek to obtain an appropriate protective order. If ▇▇. ▇▇▇▇▇▇▇▇▇▇ gives such notice to Immunomedics, but does not receive timely notice of either a protective order or a waiver from the Company and, in the written or oral opinion of his legal counsel (the reasonable fee for which opinion shall be paid or reimbursed by Immunomedics), ▇▇. ▇▇▇▇▇▇▇▇▇▇ is compelled to disclose Confidential Information or face liability for contempt or other censure or penalty, then ▇▇. ▇▇▇▇▇▇▇▇▇▇ may disclose such Confidential Information to the extent so required, without violating this provision or incurring any liability under the Agreement.

(iii) Return of Company Property. ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees that upon the termination of his employment with Immunomedics, regardless of the timing or reason for termination, he will not take or retain, without written authorization, any documents, files or other property of Immunomedics. Except as provided in this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will return promptly to Immunomedics any such documents, files or property in his possession or custody, including any copies thereof maintained in any medium or format. ▇▇. ▇▇▇▇▇▇▇▇▇▇ recognizes that all documents, files and property containing Confidential Information which he has received and will receive from Immunomedics, including but not limited to scientific research, customer lists, handbooks, memoranda, product specifications, and other materials are for the exclusive use of Immunomedics and its employees while working on behalf of Immunomedics, and that ▇▇. ▇▇▇▇▇▇▇▇▇▇ has no claim or right to the continued use, possession or custody of such documents, files or property following the termination of his employment.

Notwithstanding this provision, Immunomedics acknowledges and agrees that ▇▇. ▇▇▇▇▇▇▇▇▇▇ may retain all working documents that he determines he may need with regard to any patent(s) he is preparing for filing, pursuing, or prosecuting on behalf of Immunomedics. Immunomedics further acknowledges and agrees that any materials created prior to ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment by Immunomedics, and any materials created in connection with his employment with the Center or IBC (“Non-proprietary Materials”) are not the property of Immunomedics, and all materials that are generally available to the public and/or in the public domain (“Public Materials”), are not the exclusive property of Immunomedics. Immunomedics further agrees that ▇▇. ▇▇▇▇▇▇▇▇▇▇ may retain possession of all Non-Proprietary Materials and may retain copies of all Public Materials, at all times following the end of his employment.

(b) Non-Competition. Throughout the Term of Employment and for a period of three (3) years thereafter, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will not, without the prior written approval of the Board, whether alone or as a partner, officer, director, consultant, agent, employee or stockholder of any company or other commercial enterprise, directly or indirectly engage in any business or other activity in the United States or Canada which competes with Immunomedics. The foregoing prohibition shall not prevent ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment or

engagement following his Term of Employment, with any company or business organization, as long as the activities of any such employment or engagement, in any capacity, do not involve work on matters related to the products being researched, developed, manufactured, or marketed by Immunomedics during the Term of Employment. ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall be permitted to own securities of a public company not in excess of five percent (5%) of any class of such securities and to own stock, partnership interests or other securities of any entity not in excess of five percent (5%) of any class of such securities, and to own any amount of interest in the Center, Immunomedics, and/or in IBC (or a subsidiary or affiliate of same), and such ownership taken alone shall not be considered to be in competition with Immunomedics or a violation of this Agreement.

(c) Non-Solicitation. Throughout the Term of Employment and for a period of three (3) years thereafter, ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees that he will not:

(i) directly or indirectly solicit, entice or induce any Immunomedics’ customer to become a customer of any other person, firm or corporation with respect to products then sold or under development by Immunomedics, or to cease doing business with Immunomedics, and ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall not approach any such person, firm or corporation for such purpose or authorize or knowingly approve the taking of such actions by any other person; or

(ii) directly or indirectly solicit or recruit any employee of Immunomedics to work for a third party other than Immunomedics (excluding the Center and excluding newspaper or similar print or electronic solicitations of general circulation); provided, however, that the otherwise applicable non-solicitation period shall not be reduced in the event of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ termination for Cause or the cessation of Severance Payments as a result of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ violation of his obligations under this Section 9.

(d) Enforcement.

(i) ▇▇. ▇▇▇▇▇▇▇▇▇▇ acknowledges and agrees that the type and periods of restrictions imposed in this Section 9 of this Agreement are fair and reasonable, and that such restrictions are intended solely to protect the legitimate interests of Immunomedics, rather than to prevent ▇▇. ▇▇▇▇▇▇▇▇▇▇ from earning a livelihood. ▇▇. ▇▇▇▇▇▇▇▇▇▇ recognizes that Immunomedics competes worldwide, and that his access to Confidential Information makes it necessary for Immunomedics to restrict his post-employment activities in any market in which Immunomedics competes, and in which his access to Confidential Information and other proprietary information could be used to the detriment of Immunomedics.

(ii) Injunctive Relief. ▇▇. ▇▇▇▇▇▇▇▇▇▇ acknowledges and agrees that if he breaches any of the covenants, restrictions and agreements contained in this Section 9, Immunomedics will suffer irreparable loss and injury, and that damages arising out of such a breach may be difficult to ascertain. Therefore, ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees that, in addition to all other remedies provided at law or at equity, Immunomedics shall be entitled to have the covenants, restrictions and agreements contained in this Section 9 specifically enforced (including, without limitation, by temporary, preliminary, and permanent injunctions and restraining orders) by any state or federal court in the State of New Jersey having equity jurisdiction and ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees to be subject to the jurisdiction of such court.

(iii) Monetary Relief. In addition to its right to seek an injunction, in the event ▇▇. ▇▇▇▇▇▇▇▇▇▇ breaches any provision of this Section 9, Immunomedics also shall have the right to pursue monetary damages against ▇▇. ▇▇▇▇▇▇▇▇▇▇ for such breach.

(iv) If either party fails to take action to remedy any breach of this Agreement or any portion of this Agreement by the other party, such inaction shall not operate or be construed as a waiver of any subsequent breach by either party of the same or any other provision, agreement or covenant.

(v) ▇▇. ▇▇▇▇▇▇▇▇▇▇ acknowledges and agrees that the payments and benefits to be provided to him under this Agreement are provided, in part, as consideration for the covenants in this Section 9.

(vi) In the event that any court of competent jurisdiction or any arbitration determines that any restriction contained in this Agreement is overly broad with respect to scope, time or geographical coverage, the parties agree that such restriction(s) may be modified and narrowed, either by a court, arbitrator, or by Immunomedics only to the extent necessary to make this provision enforceable, and that such determination will not affect the enforceability of any other provision of this Agreement.

(e) Exclusions Relating to the Center. Immunomedics and ▇▇. ▇▇▇▇▇▇▇▇▇▇ agree that any work that ▇▇. ▇▇▇▇▇▇▇▇▇▇ performs for or on behalf of the Center and/or any of its affiliates, and any documents or other

confidential information or materials developed, assembled, or received while performing such work, are not subject to the provisions of this Section 9, and that any such work will not constitute a violation of the terms of this Agreement.

10. Termination. Notwithstanding the provisions of Section 2 above, the employment of ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall terminate upon the happening of any of the following events:

(a) The death of ▇▇. ▇▇▇▇▇▇▇▇▇▇.

(b) Immunomedics and ▇▇. ▇▇▇▇▇▇▇▇▇▇ mutually agree to terminate this Agreement.

(c) At Immunomedics’ option, if ▇▇. ▇▇▇▇▇▇▇▇▇▇ suffers a Permanent Disability. For purposes of this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall be deemed to have incurred a “Permanent Disability” if, by reason of his physical or mental medical condition, as determined by a physician jointly designated by Immunomedics and ▇▇. ▇▇▇▇▇▇▇▇▇▇, he is unable to perform his duties under this Agreement for a period of (i) 180 consecutive days, or (ii) 245 days in any 365 consecutive days period. ▇▇. ▇▇▇▇▇▇▇▇▇▇ will not be deemed Permanently Disabled if he submits a written opinion by a physician designated by or reasonably satisfactory to Immunomedics stating that ▇▇. ▇▇▇▇▇▇▇▇▇▇ will be able to resume continuous full-time performance of his obligations under this Agreement within 365 days following the commencement of such disability and ▇▇. ▇▇▇▇▇▇▇▇▇▇ actually returns to full-time work within the same 365 day period. In the event ▇▇. ▇▇▇▇▇▇▇▇▇▇ and Immunomedics cannot agree upon a physician to determine whether ▇▇. ▇▇▇▇▇▇▇▇▇▇ is suffering a Permanent Disability, they each may select a physician and the two physicians so selected will jointly select a third physician, who will examine ▇▇. ▇▇▇▇▇▇▇▇▇▇ to determine whether he is suffering a Permanent Disability, and will provide a written report of his/her conclusions all parties.

(d) By ▇▇. ▇▇▇▇▇▇▇▇▇▇, for Good Reason. For purposes of this Agreement, Good Reason is defined as occurrence of any of the following events or conditions, unless ▇▇. ▇▇▇▇▇▇▇▇▇▇ has expressly consented in writing thereto, or except as a result of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ physical or mental incapacity or as described in the last sentence of this subsection (d):

(i) A material reduction in ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ Base Salary;

(ii) The material diminution of the ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ duties, responsibilities, powers or authorities, including the assignment of any duties and responsibilities inconsistent with his position as Chief Scientific Officer and Chief Medical Officer of Immunomedics; or

(iii) Immunomedics requires that ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ principal office location be moved to a location more than 50 miles from his principal office location immediately before the change.

Notwithstanding the foregoing, ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall not have Good Reason for termination unless he gives written notice of termination for Good Reason within 15 days after the event giving rise to Good Reason occurs and Immunomedics does not correct the action or failure to act that constitutes the grounds for Good Reason, as set forth in ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ notice of termination, within 30 days after the date on which he gives written notice of termination and ▇▇. ▇▇▇▇▇▇▇▇▇▇ actually resigns from employment upon the expiration of the foregoing cure period. In the event of a cure of such event or condition constituting Good Reason by the Company, such event or condition shall no longer constitute Good Reason.

(e) By the Company, for “Good Cause,” which means:

(i) ▇▇. ▇▇▇▇▇▇▇▇▇▇ commits continued, knowing and intentional neglect, substantial nonperformance or a demonstrated continuing inability to perform his obligations under this Agreement (other than due to physical or mental disability) and Immunomedics provides him with written notice of such deficiencies and ninety (90) days to correct such deficiencies; or

(ii) An arbitrator or a court finds that ▇▇. ▇▇▇▇▇▇▇▇▇▇ committed an act of fraud or dishonesty related to the performance of duties under this Agreement; or

(iii) ▇▇. ▇▇▇▇▇▇▇▇▇▇ commits any material breach of any of the provisions of this Agreement other than those covered under Sections 10(e)(i) or 10(e)(ii), and fails to cure such breach within ninety (90) days after receiving written notice from Immunomedics of such breach.

(f) By ▇▇. ▇▇▇▇▇▇▇▇▇▇ upon ninety (90) days prior written notice to Immunomedics or its successor, to be effective not later than the second anniversary of a Change in Control of Immunomedics. For purposes of this Agreement, a Change of Control of Immunomedics is defined as:

(i) A merger, consolidation or reorganization approved by the Company’s stockholders, unless securities representing more than fifty percent (50%) of the total and combined voting power of the outstanding voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly, by the persons who beneficially owned the Company’s outstanding voting securities immediately prior to such transaction; or

(ii) The sale, transfer or other disposition of all or substantially all of the Company’s assets as an entirety or substantially as an entirety, occurring within a 12-month period, and representing, at a minimum, not less than 40 percent of the total gross fair market value of all assets of the Company, to any person, entity, or group of persons acting in consort, other than a sale, transfer or disposition to: (A) a shareholder of the Company in exchange for or with respect to its stock; (B) an entity, 50 percent or more of the total value or voting power of which is owned, directly or indirectly, by the Company; (C) a person, or more than one person acting as a group, that owns, directly or indirectly, 50 percent or more of the total value or voting power of the outstanding stock of the Company; or (D) an entity, at least 50 percent of the total value or voting power of which is owned by a person described in (C); or

(iii) Any transaction or series of related transactions pursuant to which any person or any group of persons comprising a “group” within the meaning of Rule 13d-5(b)(1) under the Securities Exchange Act of 1934, as amended (other than the Company or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly the beneficial owner (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company’s securities outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company’s stockholders; or

(iv) A change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the Board members ceases by reason of one or more contested elections for Board membership to be comprised of individuals whose election is endorsed by a majority of the members of the Board immediately before the date of election.

A transaction shall not constitute a Change of Control if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in the same proportions by the persons who held the Company’s securities immediately before such transaction.

(g) Except as provided in Sections 10(a), 10(c) or 10(e)(ii), with respect to death, Permanent Disability and fraud/dishonesty, respectively, termination by either party hereunder shall be effective upon the effective date of notice of such termination by the terminating party to the other party specifying the reasons, if any, for such termination.

(h) The foregoing provisions of this Section 10 notwithstanding, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will not be deemed to have had a termination of employment prior to the date as of which Immunomedics and ▇▇. ▇▇▇▇▇▇▇▇▇▇ reasonably anticipate that the level of future services to be provided by ▇▇. ▇▇▇▇▇▇▇▇▇▇ to Immunomedics, whether as an employee or an independent contractor, will permanently decrease to a level which is less than fifty (50) percent of the average level of services provided over the immediately preceding thirty-six (36) months.

11. Decisions and Determinations of the Board. Neither ▇▇. ▇▇▇▇▇▇▇▇▇▇ nor any of his affiliates shall participate in any decision by the Board, or any Board committee, which affects any of his rights or obligations under this Agreement. Except as otherwise expressly provided in this Agreement, all actions of the Board provided for in this Agreement, including but not limited to determinations, consents and approvals, shall be in the Board’s sole and uncontrolled discretion.

12. Cooperation with Immunomedics After Expiration or Termination. Following the end of the Term of Employment, regardless of timing or cause, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will cooperate fully with Immunomedics in all matters relating to the winding up of work on behalf of Immunomedics and the orderly transfer of any pending work to other employees of Immunomedics. ▇▇. ▇▇▇▇▇▇▇▇▇▇ agrees to be available and to provide services on a full-time or part-time basis, as Immunomedics may request, during the first thirty (30) calendar days following the end of his employment. In consideration for the Patent Lifetime Royalty Payments set out in Section 4.2(a)(ii) of this Agreement, ▇▇. ▇▇▇▇▇▇▇▇▇▇ specifically agrees to provide to Immunomedics all assistance reasonably necessary to

assist Immunomedics in defending and prosecuting any patents in force. This obligation will continue for the life of the patent, provided ▇▇. ▇▇▇▇▇▇▇▇▇▇ is medically able to provide such assistance. Nothing herein shall limit Immunomedics’ obligation to pay, and ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ or his estate’s right to receive, the Additional Incentive Compensation, Patent Lifetime Royalty Payments and Disposition Payments under Sections 4.2(a)(ii) and 4.2(b) of this Agreement, for the specified periods or throughout the Life of the Patents, as the case may be.

13. Payment and Benefits on Termination or Expiration.

(a) [INTENTIONALLY OMITTED]

(b) Guaranteed Payments. Not later than sixty (60) days following the termination of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment, regardless of the reason or timing of the termination, Immunomedics will make payment to ▇▇. ▇▇▇▇▇▇▇▇▇▇ for all annual Base Salary, Bonus, Minimum Payments, and Additional Incentive Compensation earned through the date of termination, any benefits accrued in accordance with the terms of any applicable benefit plans and programs of the Company (including but not limited to earned but unused vacation), and will continue all payments pursuant to Section 4.2(a)(ii) and 4.2(b) for the time periods provided in those sections of this Agreement (collectively, “Guaranteed Payments”). There are no preconditions to Immunomedics’ obligation to pay, and to ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ right to receive, Guaranteed Payments under this Section 13(b) of this Agreement.

(i) If ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment terminates pursuant to Section 10(a) (death), in addition to receiving the Guaranteed Payments, his estate will receive a Severance Payment equal to the amount of the Annual Target Bonus, if any, (pursuant to Section 4.1(b)) payable for the fiscal year in which the termination occurs (prorated to reflect ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ actual period of service during such fiscal year), such amount to be paid within sixty (60) days following the date of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ death.

(ii) If ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment terminates by mutual agreement of the parties pursuant to Section 10(b) (mutual agreement), 10(c) (permanent disability) or pursuant to expiration as set forth in Section 2, in addition to receiving the Guaranteed Payments, ▇▇. ▇▇▇▇▇▇▇▇▇▇ will receive payment for the Annual Target Bonus, if any, (pursuant to Section 4.1(b)) payable for the fiscal year in which the termination occurs (prorated to reflect ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ actual period of service during such fiscal year), such amount to be paid within sixty (60) days following the date of termination of employment, and any other benefits or payments to which the parties may agree.

(iii) If ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment terminates for Good Cause pursuant to Section 10(e), the only post-termination payment or benefit he will receive is the Guaranteed Payments.

(iv) If Immunomedics terminates ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment without Good Cause (as defined in Section 10(e)), or if ▇▇. ▇▇▇▇▇▇▇▇▇▇ terminates his employment for Good Reason pursuant to Section 10(d), in addition to the Guaranteed Payments, Immunomedics will pay ▇▇. ▇▇▇▇▇▇▇▇▇▇ a ▇▇▇▇▇▇▇▇▇ payment, paid in a lump sum, in an amount equal to three times (3x) his Total Annual Compensation (as such exists as of the date of termination), such lump sum to be paid within sixty (60) days following the date of termination of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment. “Total Annual Compensation” shall include all cash payments due to ▇▇. ▇▇▇▇▇▇▇▇▇▇ for the applicable Contract Year as set out in Sections 4.1(a) and (b), 4.2(a)(i), and 4.2(c), but shall not include payments provided pursuant to Sections 4.2(a)(ii) and 4.2(b) (which shall continue pursuant to the terms of those Sections).

(A) In the event ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment terminates as provided in Section 13(c)(iv), for a period of two (2) years following the date of termination of employment (the “Severance Period”), the Company will, to the extent permitted under the Code, continue to provide to ▇▇. ▇▇▇▇▇▇▇▇▇▇ all of the benefits of his employment, as if he remained employed, as set out in Section 5(c), except that Immunomedics shall, during the Severance Period , pay ▇▇. ▇▇▇▇▇▇▇▇▇▇ each month an amount equal to the monthly COBRA medical insurance cost under Immunomedics’ medical plan for ▇▇. ▇▇▇▇▇▇▇▇▇▇ and any eligible dependent(s) (less any required employee payments calculated as if ▇▇. ▇▇▇▇▇▇▇▇▇▇ had continued to be an employee), and all other employee benefits pursuant to Section 5(c) which are subject to COBRA. Throughout the Severance Period, in the event Immunomedics requests that ▇▇. ▇▇▇▇▇▇▇▇▇▇ provide services to Immunomedics, then Immunomedics will pay for the reasonable cost of an office and administrative assistant support for ▇▇. ▇▇▇▇▇▇▇▇▇▇, and all reasonable expenses to set up and maintain such office (including telephone, fax and Internet access, office supplies and

equipment, furniture, etc.), at a reasonable location of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ choice, but only to the extent such office, administrative assistant support and related expenses are necessary for ▇▇. ▇▇▇▇▇▇▇▇▇▇ to adequately provide such services.

(v) If ▇▇. ▇▇▇▇▇▇▇▇▇▇ terminates his employment following a Change in Control pursuant to Section 10(f), in addition to the Guaranteed Payments, Immunomedics will pay ▇▇. ▇▇▇▇▇▇▇▇▇▇, in a lump sum within sixty (60) days following the date of his termination of employment, a Severance payment in an amount equal to three times (3x) his Total Annual Compensation, as previously defined above, (as such exists as of the date of termination).

(A) In the event ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment terminates as provided in Section 13(c)(v), for or a period of three (3) years following the date of termination of employment (the “Enhanced Severance Period”), the Company or its successor, as the case may be, will, to the extent permitted under the Code, continue to provide to ▇▇. ▇▇▇▇▇▇▇▇▇▇ all of the benefits of his employment, as if he remained employed, as set out in Section 5(c), except that Immunomedics shall, during the Enhanced Severance Period, pay ▇▇. ▇▇▇▇▇▇▇▇▇▇ each month an amount equal to the monthly COBRA medical insurance cost under Immunomedics’ medical plan for ▇▇. ▇▇▇▇▇▇▇▇▇▇ and any eligible dependent(s) (less any required employee payments calculated as if ▇▇. ▇▇▇▇▇▇▇▇▇▇ had continued to be an employee), and all other employee benefits pursuant to Section 5(c) which are subject to COBRA. Throughout the Enhanced Severance Period, in the event Immunomedics requests that ▇▇. ▇▇▇▇▇▇▇▇▇▇ provide services to Immunomedics, then Immunomedics will pay for the reasonable cost of an office and administrative assistant support for ▇▇. ▇▇▇▇▇▇▇▇▇▇, and all reasonable expenses to set up and maintain such office (including telephone, fax and Internet access, office supplies and equipment, furniture, etc.), at a reasonable location of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ choice, but only to the extent such office, administrative assistant support and related expenses are necessary for ▇▇. ▇▇▇▇▇▇▇▇▇▇ to adequately provide such services.

(d) In the event ▇▇. ▇▇▇▇▇▇▇▇▇▇ should expire during either Severance Period, Immunomedics will continue to make all Severance Cash Payments to his estate through the end of the Severance Period, continue to pay his estate a monthly amount for the cost of medical coverage for ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ eligible dependents in accordance with Sections 13(c)(iv)(A) or 13(c)(v)(A), as applicable, and will continue to pay all Patent Lifetime Royalty Payments under Section 4.2(a)(ii) for the Life of each Patent.

(e) Specific Issues in the Event of a Change in Control (regardless of whether ▇▇. ▇▇▇▇▇▇▇▇▇▇ terminates his employment):

(i) Notwithstanding any provision to the contrary in the Company’s 2006 Stock Incentive Plan or any applicable plan, program or agreement, upon the occurrence of a Change of Control, all stock options, restricted stock and other equity rights held by ▇▇. ▇▇▇▇▇▇▇▇▇▇ will become fully vested and/or exercisable, as the case may be, on the date on which the Change in Control occurs, and all stock options held by ▇▇. ▇▇▇▇▇▇▇▇▇▇ shall remain exercisable, notwithstanding anything in any other agreement governing such options, for a period of twenty-four (24) months following the end of the remaining balance of the Term of the Agreement; provided, however, that in no event will the option be exercisable (a) beyond its original term; or (b) beyond the extension period permitted under Section 409A of the Code.

(ii) Notwithstanding any vesting provision to the contrary in any applicable plan, program or agreement providing for supplemental retirement benefits or deferred compensation, upon the occurrence of a Change of Control, ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ accrued benefit under such plans, programs or agreements shall become fully vested on the date on which the Change in Control occurs, and ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ accrued benefit shall be immediately payable on ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ date of termination, unless ▇▇. ▇▇▇▇▇▇▇▇▇▇ has made a valid election under such plan, program or agreement to defer payment of such accrued benefits or ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ accrued benefit constitutes “deferred compensation” within the meaning of section 409A of the Code and the terms of the applicable plan, program or agreement provides otherwise with respect to the timing of payment of the accrued benefit.

(f) Required Postponement for Specified Executives.

(i) If ▇▇. ▇▇▇▇▇▇▇▇▇▇ is considered a Specified Executive (as defined below) and payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to Section 409A of the Code, payment of such amounts shall be delayed as required by Section 409A, and the accumulated postponed amounts, with accrued interest as described below, shall be paid in a lump sum payment within five days after the end of the six month period. If ▇▇. ▇▇▇▇▇▇▇▇▇▇ dies during the postponement period prior to the payment of benefits, the amounts postponed on account of Section 409A, with accrued interest as described in subsection (b) below, shall be paid to the personal representative of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ estate within 60 days after the date of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ death.

(ii) If payment of any amounts under this Agreement is required to be delayed pursuant to Section 13(f)(i), the Company shall pay interest on the postponed payments from the date on which the amounts otherwise would have been paid to the date on which such amounts are paid at an annual rate equal to the rate published in the Wall Street Journal as the “prime rate” as of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ date of termination.

(iii) The term “Specified Executive” means an employee who, at any time during the 12-month period ending on the identification date (defined below), is (i) an officer of the Company or a member of its controlled group (as determined for purposes of section 416(i) of the Code) who has annual compensation greater than $135,000 (or such other amount as may be in effect under Section 416(i)(1) of the Code), (ii) a 5% owner of the Company or (iii) a 1% owner of the Company who has annual compensation greater than $150,000. The identification date shall be each December 31, and the determination of Specified Executives as of such identification date shall apply for the 12-month period following April 1 after the identification date. The determination of Specified Executives, including the number and identity of persons considered officers, shall be made by the Company in accordance with the provisions of Sections 416(i) and 409A of the Code and the regulations issued thereunder.

(g) Required Release. As a condition to receiving any Severance Payments under this Section (other than Guaranteed Payments, which are not subject to this condition), Immunomedics may require ▇▇. ▇▇▇▇▇▇▇▇▇▇ to execute a written release of any and all claims against the Company and all related parties with respect to all matters arising out of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ employment by the Company, or the termination thereof (the “Release”) in a form provided by the Company but acceptable to ▇▇. ▇▇▇▇▇▇▇▇▇▇. The Company hereby agrees that it will provide ▇▇. ▇▇▇▇▇▇▇▇▇▇ with the form of release agreement on or within seven days after ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ separation from service and, to be entitled to any Severance Payments under this Section 13 (other than Guaranteed Payments, which are not subject to this condition), ▇▇. ▇▇▇▇▇▇▇▇▇▇ must execute, and not revoke, it during the minimum time period permitted by applicable law. Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ execution of the Release, directly or indirectly, result in ▇▇. ▇▇▇▇▇▇▇▇▇▇ designating the calendar year of payment, and if a payment that is subject to execution of the Release could be made in more than one taxable year, payment shall be made in the later taxable year.

Subject to ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ execution and non-revocation of the Release, the Severance Payments (other than Guaranteed Payments, which are not subject to this condition) shall be paid or commence being paid within 60 days after ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ separation from service but not earlier than the date on which the Release becomes effective and not in contravention of any delay required by Section 13(f). If, however, the period during which ▇▇. ▇▇▇▇▇▇▇▇▇▇ has discretion to execute and/or revoke the Release straddles two calendar years, the Severance Payments (other than Guaranteed Payments, which are not subject to this condition) shall not be paid or commence being paid, as applicable, before the beginning of the second of the two calendar years, regardless of within which calendar year ▇▇. ▇▇▇▇▇▇▇▇▇▇ actually delivers the executed Release to the Company. Consistent with Section 409A, ▇▇. ▇▇▇▇▇▇▇▇▇▇ may not, directly or indirectly, designate the calendar year of payment.

14. [INTENTIONALLY OMITTED]

15. Parties in Interest. This Agreement is personal in nature and no party to this Agreement may assign or transfer this Agreement or any rights or obligations hereunder, without the first obtaining the express written consent of the other party.

16. Notices. All notices, proposals, submissions, offers, approvals, agreements, elections, consents, acceptances, waivers, reports, plans, requests, instructions, options or other exercise of rights, and other communications required or permitted to be made or given hereunder (all of the foregoing hereinafter collectively referred to as “communications”) shall be in writing, signed by or on behalf of the notifying party, and shall be deemed to have been duly made or given when (i) delivered personally with receipt acknowledged, (ii) sent by registered or certified mail or equivalent, return receipt requested, (iii) sent by facsimile or (iv) sent by recognized overnight courier for delivery within 48 hours, in each case addressed or sent to the parties at the following addresses or facsimile numbers or to such other or additional address or facsimile number as any party shall hereafter specify by Communication to the other parties:


To:				Immunomedics, Inc.

				▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇

				▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇

				Attn: Chief Executive Officer

				and Corporate Secretary

				Fax #: (▇▇▇) ▇▇▇-▇▇▇▇

with a copy to (which shall not constitute notice):				▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Esq.

				DLA Piper LLP (US)

				▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇

				▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇

				Fax #: (▇▇▇) ▇▇▇-▇▇▇▇

To:				▇▇. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇ at the address provided to the Company

with a copy to (which shall not constitute notice):				▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Esq.

				▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ LLC

				▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇., ▇▇▇▇▇ ▇▇▇

				▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇

				Fax #: (▇▇▇) ▇▇▇-▇▇▇▇

or to the appropriate attorney of record for Immunomedics or ▇▇. ▇▇▇▇▇▇▇▇▇▇, respectively. Notice of change of address shall be deemed given when actually received or upon refusal to accept delivery thereof; all other communications shall be deemed to have been given, received and dated on the earliest of: (1) when actually received or upon refusal to accept delivery thereof, (ii) on the date when delivered personally, (iii) one (1) day after being sent by facsimile or telex, (iv) 48 hours after being sent by overnight courier and (v) three (3) business days after mailing.

17. Governing Law. This Agreement and the rights of the parties hereunder shall be governed by and construed in accordance with the laws of the state of New Jersey, without giving effect to the principles of conflict of laws.

(a) Section 409A of the Code. This Agreement is intended to comply with Section 409A of the Code and its corresponding regulations, to the extent applicable, and shall be so construed. Notwithstanding anything in this Agreement to the contrary, payments may only be made under this Agreement upon an event and in a manner permitted by Section 409A of the Code, to the extent applicable. For purposes of Section 409A of the Code, each payment under this Agreement shall be treated as a separate payment and the right to a series of installment payments shall be treated as the right to a series of separate payments. All reimbursements or in-kind benefits provided under this Agreement shall be made or provided in accordance with Section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ lifetime (or during a shorter time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement or the amount of in-kind benefits provided during a calendar year may not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other calendar year, except for any medical reimbursement arrangement providing for the reimbursement of expenses referred to in Section 105(b) of the Code, (iii) the reimbursement of an eligible expense will be made on or before the last day of the taxable year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. Nothing herein shall be construed as having modified the time and form of payment of any amounts or payments of “deferred compensation” within the meaning section 409A of the Code that were otherwise payable pursuant to the terms of any agreement between Company and ▇▇. ▇▇▇▇▇▇▇▇▇▇ in effect on or after January 1, 2005 and prior to the date of this Agreement. If ▇▇. ▇▇▇▇▇▇▇▇▇▇ is considered a specified employee (as defined under Section 409A of the Code) and payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to section 409A of the Code, payment of such amounts shall be delayed as required by section 409A of the Code, and the accumulated postponed amounts, with accrued interest as described below, shall be paid in a lump sum payment within five days after the end of the six month period. If ▇▇. ▇▇▇▇▇▇▇▇▇▇ dies during the postponement period prior to the payment of benefits, the amounts postponed on account of section 409A of the Code, with accrued interest as described below, shall be paid to the personal representative of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ estate within 60 days after the date of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ death. If payment of any amounts under this Agreement is required to be delayed pursuant to the preceding sentence, the Company shall pay interest on the postponed payments from the date on which the amounts otherwise would have been paid to the date on which such amounts are paid at an annual rate equal to the rate published in the Wall Street Journal as the “prime rate” as of ▇▇. ▇▇▇▇▇▇▇▇▇▇’▇ date of termination.

18. Captions; Word Meanings. Captions contained in this Agreement are inserted only as a matter of convenience and in no way define, limit or extend the scope of this Agreement or any provision hereof. The words “hereby”, “herein”, “hereinabove”, “hereinafter”, “hereof” and “hereunder”, when used anywhere in this Agreement, refer to this Agreement as a whole and not merely to a subdivision in which such words appear, unless the context otherwise requires. The singular shall include the plural, the conjunctive shall include the disjunctive and the masculine gender shall include the feminine and neuter, and vice versa, unless the context otherwise requires.

19. Miscellaneous.

(a) Proration. Wherever in this Agreement there is provision for proration of Annual Net Sales or any other calculation for any partial fiscal year, such proration shall be effected by multiplying the total Annual Net Sales or other annualized figure as the case may be, by a fraction, the numerator of which shall be the actual number of days included in such partial fiscal year and the denominator of which shall be 365.

(b) Offsets. Wherever provision is made in this Agreement for the payment of any amounts by one party hereto to another, such amounts either may be paid directly by the party obligated to make the payments to the other party or, at the option of the party obligated to make such payments and with the consent of the other party, the obligated party may offset the amounts it is obligated to pay against all or part of any amounts owed that the other party is obligated to pay the first party, pursuant to or in connection with this Agreement, but not in contravention of any deferred compensation offset prohibition under section 409A of the Code.

20. Binding Effect. This Agreement and all the terms and provisions hereof shall be binding upon and shall inure to the benefit of the parties, their respective legal representatives, heirs, successors and permitted assigns.

21. Entire Agreement. This Agreement, together with the documents specifically referenced herein, each of which is incorporated by reference and be governed by the provisions of this Agreement constitutes the entire agreement between the parties. This Agreement supersedes and replaces any other prior agreement or understandings between ▇▇. ▇▇▇▇▇▇▇▇▇▇ and Immunomedics on any subject covered by this Agreement. This Agreement may not be modified or amended in any manner other than in writing executed by or on behalf of both parties on a date subsequent to the date of this Agreement.

22. Severability. If an arbitrator or court of competent jurisdiction should determine that any provision of this Agreement is overly broad in scope or duration, prohibited or unenforceable, the parties may meet and attempt to reach agreement on a mutually acceptable modification that would be enforceable. If the parties cannot reach agreement on a modification within a reasonable time period, the arbitrator or court shall have the authority to modify that portion of the Agreement only to the minimal extent possible to make it legally enforceable, and the balance of the Agreement shall remain in force without regard for the prohibited portion.

23. Survival of Provisions. The provisions of Sections 4.1, 4.2, 5, 7, 8 through 13, 15, 16, 17, 19, 22 and 23 of this Agreement, and the provisions of any agreement incorporated by reference herein, shall survive expiration of the term or termination of employment for any reason.

24. Counterparts. This Agreement is written in the English language and may be executed in any number of English language counterparts and each such duplicate counterpart shall constitute an original, any one of which may be introduced in evidence or used for any other purpose without the production of its duplicate counterpart. Moreover, notwithstanding that any of the parties did not execute the same counterpart, each counterpart shall be deemed for all purposes to be an original, and all such counterparts shall constitute one and the same instrument, binding on all of the parties hereto.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day, month and year first above written.


IMMUNOMEDICS, INC.
(“Immunomedics”)

By:		/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
		▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇
		Senior Vice President, Finance and Business Development, and Chief Financial Officer

		/s/ ▇▇. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
		▇▇. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇▇
		(“▇▇. ▇▇▇▇▇▇▇▇▇▇”)

EX-10.2 3 dex102.htm THIRD AMENDED AND RESTATED EMPLOYMENT AGREEMENT Third Amended and Restated Employment Agreement by and between Immunomedics, Inc. and Dr. David M. Goldenberg Dated as of July 1, 2011 Page THIRD AMENDED AND RESTATED EMPLOYMENT...

Document Metadata

Document Metadata

Table of Contents